婴儿期诊断的进展性视交叉-下丘脑胶质瘤患儿的当前与新兴治疗策略:一项网络调查
该网络调查向SIOPE脑肿瘤组成员发放问卷,了解进展性婴儿视交叉-下丘脑胶质瘤(iCHG)的二线和三线治疗策略,共回收15个国家47名儿科肿瘤医生的答复。一线卡铂-长春新碱治疗期间进展者,36%考虑替代化疗,58%考虑手术联合化疗;三线治疗中53%考虑贝伐珠单抗(常联合伊立替康40%),34%考虑长春碱。多种抗肿瘤药物方案用于进展性iCHG,贝伐珠单抗在三线治疗中应用较普遍。
要点
- 一线卡铂-长春新碱期间进展的iCHG,36%受访者考虑替代化疗,58%考虑手术联合化疗。
- 二线治疗建议成分包括长春碱62%、顺铂34%、环磷酰胺26%。
- 三线治疗53%受访者认为贝伐珠单抗合适(常联合伊立替康40%),34%考虑长春碱。
核心结论
- 多种抗肿瘤药物方案用于进展性iCHG,部分考虑在安全可行时联合手术。
- 贝伐珠单抗在三线治疗中应用较普遍,主要联合伊立替康。
研究设计与样本
- 网络问卷调查,发送给SIOPE脑肿瘤组成员,询问一线治疗期间及结束后进展时的二线和三线策略。
- 问卷由15个国家的47名儿科肿瘤医生回答。
主要发现
- 一线卡铂-长春新碱治疗期间进展的iCHG,17名(36%)受访者考虑替代化疗,27名(58%)考虑手术联合化疗。
- 二线治疗建议成分:长春碱62%、顺铂34%、环磷酰胺26%。
- 三线治疗:53%受访者认为贝伐珠单抗合适(常联合伊立替康40%),34%考虑长春碱。
- 53%受访者报告贝伐珠单抗用于CHG的经验,涉及至少95例患者(每位受访者中位治疗1-5例任何年龄患者),中位给药12个月。
- 疗效报告从疾病稳定到消退不等,并发症罕见报告(蛋白尿、高血压、出血)。
临床怎么用
- 进展性iCHG可应用多种抗肿瘤药物方案,部分考虑在安全可行时联合手术。
- 贝伐珠单抗在三线治疗中应用较普遍,主要联合伊立替康。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of infant hypothalamic chiasmatic glioma (iCHG) is challenging, about 30% of the children progress during chemotherapy. Despite subsequent treatments the 5 year overall-survival rate is only 70%. This study investigates treatment strategies currently applied for progressive iCHG. A web-based questionnaire was sent out to the members of the SIOPE Brain Tumour Group asking for current second and third line strategies at progression during and after the end of first line therapy. The questionnaire was answered by 47 paediatric oncologists from 15 countries. iCHG progressing during first line therapy with carboplatin-vincristine would be considered for treatment with alternative chemotherapy by 17 (36%) and with surgery plus chemotherapy by 27 respondents (58%). Components suggested for second line were vinblastine (62%), cisplatin (34%) and cyclophosphamide (26%). For third line therapy bevacizumab (BVZ) was considered as suitable by respondents in 53% (often with irinotecan 40%) and vinblastine by 34% respectively. Experience with BVZ in CHG is shown by 53% of respondents regarding at least 95 patients (median treated 1-5 patients per respondent at any age) with a median BVZ administration over 12 months. Effectiveness was reported varying between stable disease and regression while complications were rarely stated (proteinuria, hypertension, bleeding). BVZ would be available to 85% of respondents as therapeutic option for iCHG patients. Multiple anti-neoplastic drug regimens are applied for progressive iCHG, partly considered in combination with surgery if safely feasible. BVZ is commonly used at a satisfactory level in third line, mainly combined with irinotecan.
引用
- Azizi AA, Schouten-van Meeteren AYN. Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey. J Neurooncol. 2017. PMID: 29071540. doi:10.1007/s11060-017-2630-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。